You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 344 Comparative assessment of product quality attributes associated with production of chimeric antigen receptor T cells expressing scFv CD-19 and scFv IL-13Ra2 by two manufacturing platforms

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cell Therapies
344 Comparative assessment of product quality attributes associated with production of chimeric antigen receptor T cells expressing scFv CD-19 and scFv IL-13Ra2 by two manufacturing platforms
Free

Authors

Citation

Hwang S, Degheidy H, McCann M, et al
344 Comparative assessment of product quality attributes associated with production of chimeric antigen receptor T cells expressing scFv CD-19 and scFv IL-13Ra2 by two manufacturing platforms
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0344

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.